Der Gastroenterologe

, Volume 8, Issue 6, pp 517–524

Die nichtalkoholische Steatohepatitis als viszerale Manifestation des metabolischen Syndroms

Schwerpunkt
  • 189 Downloads

Zusammenfassung

Die nichtalkoholische Fettleberkrankheit (NAFLK) ist in den Industrieländern eine der häufigsten chronischen Leberkrankheiten und die dritthäufigste Indikation zur Lebertransplantation in den Vereinigten Staaten. Sie kommt im Kindes- und Erwachsenenalter vor und gilt als hepatische Manifestation des metabolischen Syndroms. Klinische Verläufe haben die formale Sequenz von NAFLK über Steatohepatitis zu Leberzirrhose zweifelsfrei bewiesen. Patienten mit manifester Steatohepatitis haben ein größeres Risiko für das Auftreten kardiovaskulärer Erkrankungen und ein erhöhtes Krebserkrankungsrisiko. Die Leberbiopsie ist unverändert der Goldstandard für die Diagnosesicherung.

Schlüsselwörter

Lebererkrankungen Metabolisches Syndrom Steatohepatitis Nichtalkoholische Fettleberkrankheit Leberzellkarzinom 

Non-alcoholic fatty liver disease as a visceral manifestation of metabolic syndrome

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in developed countries. It is the third most common indication for liver transplantation in the United States. NAFLD affects children and adults. It is considered to be the hepatic manifestation of metabolic syndrome. Clinical case histories validated the progression of NFALD to steatohepatitis and frank liver cirrhosis. Patients with steatohepatitis are at increased risk to suffer from cardiovascular disease and even cancer. Liver biopsy currently remains the gold standard for the diagnosis.

Keywords

Liver disease Metabolic syndrome Steatohepatitis Non-alcoholic fatty liver disease Hepatocellular carcinoma 

Literatur

  1. 1.
    National Cholesterol Education Program (2001) Executive Summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285: 2486–2497CrossRefGoogle Scholar
  2. 2.
    Ahrens M, Ammerpohl O, Kolarova J et al (2013) DNA methylation analysis in nonalcoholic Fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18: 296–302PubMedCrossRefGoogle Scholar
  3. 3.
    Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640–1645PubMedCrossRefGoogle Scholar
  4. 4.
    Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome – a new worldwide definition. Lancet 366: 1059–1062PubMedCrossRefGoogle Scholar
  5. 5.
    Bremer AA, Jialal I (2013) Adipose tissue dysfunction in nascent metabolic syndrome. J Obes 2013: 393192PubMedCrossRefGoogle Scholar
  6. 6.
    Brunt EM (2012) Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Dig Dis 30 (Suppl 1): 61–68PubMedCrossRefGoogle Scholar
  7. 7.
    Brunt EM, Kleiner DE, Wilson LA et al (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53: 810–820PubMedCrossRefGoogle Scholar
  8. 8.
    Chalasani N, Younossi Z, Lavine JE et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592–1609PubMedCrossRefGoogle Scholar
  9. 9.
    Charlton MR, Burns JM, Pedersen RA et al (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249–1253PubMedCrossRefGoogle Scholar
  10. 10.
    Denzer C (2013) Non-alcoholic fatty liver disease in obese children and adolescents. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 56: 517–527CrossRefGoogle Scholar
  11. 11.
    Hsu E, Murray K (2012) Is nonalcoholic fatty liver disease in children the same disease as in adults? Clin Liver Dis 16: 587–598PubMedCrossRefGoogle Scholar
  12. 12.
    Kleiner DE, Brunt EM (2012) Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 32: 3–13PubMedCrossRefGoogle Scholar
  13. 13.
    Kleiner DE, Brunt EM, Van NM et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313–1321PubMedCrossRefGoogle Scholar
  14. 14.
    Levene AP, Goldin RD (2012) The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61: 141–152PubMedCrossRefGoogle Scholar
  15. 15.
    Loria P, Adinolfi LE, Bellentani S et al (2010) Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 42: 272–282PubMedCrossRefGoogle Scholar
  16. 16.
    Machado MV, Cortez-Pinto H (2013) Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 58: 1007–1019PubMedCrossRefGoogle Scholar
  17. 17.
    Masuoka HC, Chalasani N (2013) Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann NY Acad Sci 1281: 106–122PubMedCrossRefGoogle Scholar
  18. 18.
    Naik A, Kosir R, Rozman D (2013) Genomic aspects of NAFLD pathogenesis. Genomics 102: 84–95PubMedCrossRefGoogle Scholar
  19. 19.
    Nascimbeni F, Pais R, Bellentani S et al (2013) From NAFLD in clinical practice to answers from guidelines. J Hepatol 59:859–871PubMedCrossRefGoogle Scholar
  20. 20.
    Ovchinsky N, Moreira RK, Lefkowitch JH et al (2012) Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol 19: 250–262PubMedCrossRefGoogle Scholar
  21. 21.
    Pais R, Pascale A, Fedchuck L et al (2011) Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 35: 23–28PubMedCrossRefGoogle Scholar
  22. 22.
    Piscaglia F, Marinelli S, Bota S et al (2013) The role of ultrasound elastographic techniques in chronic liver disease: current status and future perspectives. Eur J Radiol. doi:pii: S0720-048X(13)00326-4Google Scholar
  23. 23.
    Rafiq N, Bai C, Fang Y et al (2009) Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7: 234–238PubMedCrossRefGoogle Scholar
  24. 24.
    Schuppan D, Schattenberg JM (2013) Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 28 (Suppl 1): 68–76PubMedCrossRefGoogle Scholar
  25. 25.
    Tannapfel A, Denk H, Dienes HP et al (2010) Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines. Pathologe 31: 225–237Google Scholar
  26. 26.
    White DL, Kanwal F, El-Serag HB (2012) Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10: 1342–1359PubMedCrossRefGoogle Scholar
  27. 27.
    Younossi ZM, Stepanova M, Rafiq N et al (2011) Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53: 1874–1882PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Institut für PathologieChristian-Albrechts-UniversitätKielDeutschland

Personalised recommendations